AVBP Company Profile and Key Details

AVBP has shown sold momentum, gaining 8.9% over the past week and 14.1% over the past quarter, though year-to-date performance is up 10.64%. Short-term trend indicators are mixed aligned (SMA20 5.52%, SMA50 3.36%, SMA200 8.86%). The stock’s 14-day RSI is 54.91 (neutral), while the ATR of 1.43 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -25.08% below its high and over 43.89% above its low. Average 10-day trading volume of 352.44 thousand shares is in line with the 3-month average of 374.79 thousand, indicating normal recent market interest.

Wall Street analysts project EPS growth of -3.47% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 14 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $45.00 to $31.00. The high target offers 102.16% upside. The low target suggests 39.26% downside. The mean target is $39.20. This offers 76.1% upside. ArriVent BioPharma, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended November 10, 2025, missed forecasts by 6.41%. The prior quarter beat by 28.57%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in August 14, 2024.

ArriVent BioPharma, Inc. Common Stock has 41.28 million shares outstanding. The public float is 22.71 million shares, elevated short interest at 21.72% of float. This equals 6.75 million shares. The short ratio is 18.27 days. Institutional investors hold 107.77% of the float. Insiders own 8.1%. HILLHOUSE INVESTMENT MANAGEMENT, LTD. holds 4.48 million shares, HEALY JAMES has 1.70 million shares and GORDON CARL L has 1.51 million shares.

ArriVent BioPharma, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.36. This means the shares are trading above this model’s fair value.

ArriVent BioPharma, Inc. Common Stock (NASDAQ:AVBP) closed at $22.82 USD, gaining $0.56 (2.52%) from the previous close of $22.26. The stock is currently mid-range between its 52-week high and low $15.47 and $29.71. With a market capitalization of about $942.04 million, ArriVent BioPharma, Inc. Common Stock is classified as a small-cap and shows market-like volatility (beta ~1.04). Key stats such as the average daily volume over the past year has been around 393.26 thousand shares, in line with its 52-week average. Headquartered in Newtown Square, None, ArriVent BioPharma, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Zhengbin Yao, the company employs approximately 52 people and listed since January 26, 2024. ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.

Our AI price prediction model suggests that ArriVent BioPharma, Inc. Common Stock stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -4.67%, with price expected at $21.22 by February 03, 2026, within a range of $19.72 to $22.58 3-Month Outlook: Projected fall of -3.77%, reaching $21.42 by April 16, 2026, with a range of $20.42 to $22.48. 1-Year Outlook: Projected loss of -3.14%, with price at $21.56 by January 15, 2027, within a range of $20.34 to $23.13.

ArriVent BioPharma, Inc. Common Stock (NASDAQ:AVBP) shares are up 10.64% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows ArriVent BioPharma, Inc. Common Stock trading at a premium to the broader market with a P/E of -6.11. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $38.16, suggesting 71.43% upside. Our AI forecast model points to short-term weakness (-4.67% over two weeks), a medium-term fall (-3.77% over three months), and a longer-term loss (-3.14% over one year), with expected trading ranges indicating moderate volatility.

ArriVent BioPharma, Inc. Common Stock trades at a P/E ratio of -6.11, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.03 trading at moderately above to book value. The P/FCF stands at -6.24, also below market averages.